Genscript Biotech (01548): Legend announces presentation at the American Society of Hematology Annual Meeting

Zhitong Finance APP News, GenScript Biotech Corporation (01548) issued an announcement that Legend Biotech Corporation ("Legend," an associate of the Company, whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American Depositary Shares) submitted Form 6-K to the U.S. Securities and Exchange Commission on November 4, 2026 (New York time) (after the Hong Kong trading session on November 4, 2026). It also announced that at the 68th American Society of Hematology Annual Meeting, to be held from December 12 to 15, 2026, in New Orleans, Louisiana, United States, it will present research results on CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of multiple myeloma in two oral presentations, two poster presentations, and one electronic publication. In addition to the CARVYKTI data, Legend will also present in poster form its allogeneic gamma-delta CAR-T cell therapy LUCAR G39D targeting the CD20/CD19 dual target for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, as well as in poster form its first in vivo CD19/CD20 dual-target CAR-T therapy LB2501, which is being evaluated for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.